The epidemiology of asthma and its comorbidities in Poland – Health problems of patients with severe asthma as evidenced in the Province of Lodz.

Related Articles

The epidemiology of asthma and its comorbidities in Poland – Health problems of patients with severe asthma as evidenced in the Province of Lodz.

Respir Med. 2016 Jan 20;

Authors: Panek M, Mokros ?, Pietras T, Kuna P

Abstract
INTRODUCTION: Population studies supply interesting data regarding the epidemiology, comorbidity and risk factors of asthma, which have direct clinical implications for patients.
OBJECTIVES: The aim of the work was to evaluate the degree of severity of asthma in the studied group, the levels of anti-asthma treatment, the prevalence of asthma comorbidities and their influence on the clinical course of the illness.
PATIENTS AND METHODS: The study encompassed 451 participants: 52.11% were asthma patients (study group) and 47.89% were healthy subjects (controls). Respiratory function tests, ACT™ test and skin prick tests were performed.
RESULTS: Asthma severity was mild in 14.89%, moderate in 49.36% and severe in 35.74%. Oral GCS were used by 29%, inhalers 44%, LABA 68%, SABA 67%, LAMA 6%, SAMA 14% and MX 16%. Rhinitis and allergy were significantly more common in patients. GERD and neurological diseases were risk factors for asthma, and GERD significantly intensified the risk of severe asthma. GERD, atherosclerosis, hypertension, ischaemic heart disease and other cardiac diseases, lipid disorders, COPD, and the presence of any neoplastic disease significantly worsened the degree of asthma control.
DISCUSSION: Severe asthma was a significant clinical issue in over 35% of cases. The most commonly-used group of drugs were LABAs, while inhaled GCS and LAMA were uncommon, especially among severe cases. A significant problem was the high percentage of systemic GCS used by severe cases. The most important risk factor for asthma, including its severe form, is GERD. Numerous comorbid conditions significantly worsen the degree of asthma control.

PMID: 26852088 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

New Market Research Report: EpiCast Report: Asthma – Epidemiology Forecast … – SBWire (press release)

New Market Research Report: EpiCast Report: Asthma – Epidemiology Forecast
SBWire (press release)
Boston, MA — (SBWIRE) — 07/06/2013 — Asthma is one of the most common chronic diseases in the world, with an estimated 300 million people suffering from the disease in 2004 (Masoli et al., 2004). The 2004 Global Initiative for Asthma (GINA) report 

View full post on asthma – Google News

EpiCast Report: Asthma – Epidemiology Forecast to 2022 – PR Newswire (press release)

EpiCast Report: Asthma – Epidemiology Forecast to 2022
PR Newswire (press release)
Asthma is one of the most common chronic diseases in the world, with an estimated 300 million people suffering from the disease in 2004 (Masoli et al., 2004). The 2004 Global Initiative for Asthma (GINA) report estimated that prevalence of asthma in

and more »

View full post on asthma – Google News

Influence of asthma epidemiology on the risk for other diseases.

Influence of asthma epidemiology on the risk for other diseases.

Allergy Asthma Immunol Res. 2012 May;4(3):122-31

Authors: Juhn YJ

Abstract
Asthma is a multifactorial chronic disease affecting a significant proportion of people in the United States and worldwide. Numerous laboratory and epidemiological studies have attempted to understand the etiology and underlying mechanisms of asthma and to identify effective therapies. However, the impact of asthma on the risk for other diseases has drawn little attention. This paper discusses the potential effects of asthma as a risk factor for other diseases, explores the potential mechanisms, and reviews the implications of the findings to clinical practice, public health, and research.

PMID: 22548204 [PubMed – in process]

View full post on pubmed: asthma